US2013142805A1PendingUtilityA1

Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases

67
Assignee: BRISTOL MYERS SQUIBB COPriority: Aug 1, 2008Filed: Feb 14, 2013Published: Jun 6, 2013
Est. expiryAug 1, 2028(~2 yrs left)· nominal 20-yr term from priority
Inventors:Maria Jure-KunkelFrancis Y. Lee
A61K 45/06A61K 31/555A61K 31/7068A61K 31/505A61P 35/00A61K 39/3955A61K 39/39541A61K 33/24A61K 33/243
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.

Claims

exact text as granted — not AI-modified
1 - 14 . (canceled) 
     
     
         15 . A method for the treatment of cancer, comprising the administration to a mammal in need thereof a synergistic, therapeutically effective amount of an anti-CTLA-4 antibody with 2′-deoxy-2′,2′-difluorocytidine monohydrochloride (β-isomer), or a pharmaceutically acceptable salt, solvate, or hydrate thereof. 
     
     
         16 . The method according to  claim 15 , wherein the anti-CTLA-4 antibody is selected from the group consisting of: ipilimumab and tremelimumab. 
     
     
         17 . The method according to  claim 15 , wherein said anti-CTLA-4 antibody is ipilimumab. 
     
     
         18 . The method according to  claim 15 , wherein said cancer is a solid tumor. 
     
     
         19 . The method according to  claim 18 , wherein said solid tumor is selected from the group consisting of: lung carcinoma, lung metastasis, and colon carcinoma. 
     
     
         20 . The method according to  claim 15 , wherein said method is for the treatment of a tumor refractory to said chemotherapeutic agent. 
     
     
         21 . The method according to  claim 15 , wherein said chemotherapeutic agent is administered before the administration of said anti-CTLA4 antibody. 
     
     
         22 . The method according to  claim 15 , wherein said chemotherapeutic agent is administered essentially simultaneously with the administration of said anti-CTLA4 antibody. 
     
     
         23 . The method according to  claim 15 , wherein said cancer treatment further comprises an anti-proliferative cytotoxic agent either alone or in combination with radiation therapy. 
     
     
         24 . The method according to  claim 23 , wherein said anti-proliferative cytotoxic agent is cisplatin. 
     
     
         25 . The method according to  claim 23 , wherein said anti-proliferative cytotoxic agent is paraplatin. 
     
     
         26 . The method according to  claim 15 , wherein said chemotherapeutic agent is administered at a dose of about 200 mg. 
     
     
         27 . The method according to  claim 15 , wherein said chemotherapeutic agent is administered at a dose of about 1 g. 
     
     
         28 . The method according to  claim 15 , wherein said chemotherapeutic agent is administered via IV infusion. 
     
     
         29 . The method according to  claim 15 , wherein said anti-CTLA4 antibody is administered about every three weeks. 
     
     
         30 . The method according to  claim 18 , wherein said solid tumor is lung carcinoma. 
     
     
         31 . The method according to  claim 18 , wherein said solid tumor is lung metastasis. 
     
     
         32 . The method according to  claim 18 , wherein said solid tumor is colon carcinoma.

Join the waitlist — get patent alerts

Track US2013142805A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.